[In vitro experimental study of gene therapy for ovarian cancer with thymidine kinase gene of herpes simplex virus mediated by a non-viral GE7 delivery system]

Zhonghua Fu Chan Ke Za Zhi. 2003 Oct;38(10):621-4.
[Article in Chinese]

Abstract

Objective: To investigate gene transfer efficiency of a novel target non-viral vector GE7 and effects of herpes simplex virus thymidine kinase (HSV(1)-tk)/ganciclovir (GCV) mediated by it in vitro.

Methods: The epidermal growth factor receptor (EGF-R) target gene delivery system GE7 was constructed. Human ovarian cancer cell line CAOV3 was transfected in vitro with beta-galactosidase (beta-gal) as reporter gene and HSV(1)-tk gene as therapeutic gene using this gene delivery system. By means of the assay of X-gal staining, Northern blotting, cell growth-inhibiting curve and so on, the transferring efficiency of exogenous genes and killing effects are observed.

Results: It showed that gene transfer efficiency is over 80%. When 10 mg/L GCV was put into ovarian cells transfected with HSV(1)-tk gene, 95% of cells were killed, and the apoptosis ratio reached up to 30.

Conclusions: The GE7 gene delivery system is an effective and safe delivery system. GE7/HSV(1)-tk/GCV therapeutic gene system is appraising for ovarian cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Division
  • ErbB Receptors / genetics*
  • Female
  • Flow Cytometry
  • Ganciclovir / therapeutic use
  • Genetic Therapy / methods*
  • Genetic Vectors
  • Humans
  • Ovarian Neoplasms / therapy*
  • Simplexvirus / enzymology*
  • Thymidine Kinase / genetics*

Substances

  • Thymidine Kinase
  • ErbB Receptors
  • Ganciclovir